Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1‐6 and compensated cirrhosis or advanced fibrosis

Publisher： John Wiley & Sons Inc

E-ISSN： 1478-3231|38|3|443-450

ISSN： 1478-3223

Source： LIVER INTERNATIONAL (ELECTRONIC), Vol.38, Iss.3, 2018-03, pp. : 443-450

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis

By  

HEPATOLOGY, Vol. 62, Iss. 1, 2015-07 ,pp. : 79-86

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C–Infected Patients With Compensated and Decompensated Cirrhosis

By  

HEPATOLOGY, Vol. 62, Iss. 3, 2015-09 ,pp. : 715-725

John Wiley & Sons Inc

Access to resources Recommend Favorite

Liver stiffness predicts clinical outcome in human immunodeficiency virus/hepatitis C virus‐coinfected patients with compensated liver cirrhosis

By  

HEPATOLOGY, Vol. 56, Iss. 1, 2012-07 ,pp. : 228-238

John Wiley & Sons Inc

Access to resources Recommend Favorite

Benefit‐risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration's evaluation

By  

HEPATOLOGY, Vol. 67, Iss. 2, 2018-02 ,pp. : 482-491

John Wiley & Sons Inc

Access to resources Recommend Favorite

Resistance characterization of ledipasvir and velpatasvir in hepatitis C virus genotype 4

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 25, Iss. 2, 2018-02 ,pp. : 134-143

John Wiley & Sons Inc

Access to resources Recommend Favorite